Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms

BCL-xL, a Mitochondrial Protein Involved in Successful Aging: From C. elegans to Human Centenarians

(2020) Consuelo Borrás et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts

(2020) Jessica Petiti et al.   Journal of Clinical Medicine

Curcumin induces apoptosis in JAK2‐mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways

(2019) Jessica Petiti et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells

(2019) Valentina Rosso et al.   Journal of Clinical Medicine

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis

(2018) Denis Tvorogov et al.   Science Advances

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Leukemic Transformation in Myeloproliferative Neoplasms

(2017) Meera Yogarajah et al.   MAYO CLINIC PROCEEDINGS

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin

(2016) T Balligand et al.   LEUKEMIA

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

(2015) Alessandro M. Vannucchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors

(2015) S Cerquozzi et al.   Blood Cancer Journal

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells

(2015) Lucia Mazzacurati et al.   Oncotarget

ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway

(2014) Marco Lo Iacono et al.   INTERNATIONAL JOURNAL OF CANCER

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

(2013) Michaela Waibel et al.   Cell Reports

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis

(2012) Raquel Tognon et al.   Journal of Hematology & Oncology

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

Down-regulation of the JAK2/PI3K-mediated signaling activation is involved in Taiwan cobra cardiotoxin III-induced apoptosis of human breast MDA-MB-231 cancer cells

(2010) Kuei-Li Lin et al.   TOXICON

Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells

(2008) A. Zeuner et al.   BLOOD

ABT-737, proving to be a great tool even before it is proven in the clinic

(2008) D L Vaux   CELL DEATH AND DIFFERENTIATION